Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 May-Jun;64(3):273-9.
doi: 10.1016/S0019-4832(12)60086-8.

Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study

Ashok S Thakkar  1 , Atul D Abhyankar, Sameer I Dani, Darshan N Banker, Parvinder I Singh, Sanjay A Parmar, Anita A Mehta
Affiliations
Clinical Trial

Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study

Ashok S Thakkar et al. Indian Heart J. 2012 May-Jun.

Abstract

Objectives: This study was conducted to assess the systemic drug release and distribution of sirolimus-eluting coronary stents.

Methods: Twenty patients with coronary artery disease (CAD) were treated with 1, 2, or 3 a newly designed metallic stents. Blood samples were drawn at 14 time points to determine the pharmacokinetic of sirolimus. Whole blood concentrations of sirolimus were determined by using a sensitive validated high-performance liquid chromatography mass spectrometry/mass spectrometry method.

Results: Minimal measurable blood levels were detectable at 7 days. Across all dose levels, individual T(max) values ranged from 1.00 hour and 12.00 hours; individual C(max) ranged from 0.73 ng/mL and 4.13 ng/mL.

Conclusion: This study confirms the limited exposure of the systemic circulation of the eluted drug with the use of the Supralimus-Core® Sirolimus-Eluting Coronary Stent System (Sahajanand Medical Technologies Pvt. Ltd., Surat, India). In this study, sirolimus concentration in systemic circulation is to be safe, well-tolerated and short-lived.

PubMed Disclaimer

References

    1. Bertrand OF, Sipehia R, Mongrain R. Biocompatibility aspects of new stent technology. J Am Coll Cardiol. 1998;32:562–571. - PubMed
    1. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104:600–605. - PubMed
    1. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res. 2000;86:879–884. - PubMed
    1. Fajadet J, Morice MC, Bode C. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation. 2005;111:1040–1044. - PubMed
    1. Holmes DR, Jr, Leon MB, Moses JW. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634–640. - PubMed

Publication types

LinkOut - more resources